Abstract
Liposomal delivery mechanisms are increasingly being seen as a useful vehicle to deliver drugs to the body. A new liposomal formulation has been developed to enable specific targeting of chemotherapy to tumours, delegates were told at the 23rd European Society for Medical Oncology Congress [ Athens, Greece; November 1998 ]. Pegylated-liposomal doxorubicin appears to have superior efficacy over existing therapies in Kaposi’s sarcoma, and evidence is starting to show that it is active in other cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
